The Filing Desk

Celularity vs Cue Biopharma

Celularity CELU · Cue Biopharma CUE · Pharmaceuticals

Cue Biopharma reported revenue of $28 million in fiscal 2025, about the same as Celularity's $26 million in fiscal 2025. Celularity's revenue fell 51.0% in its latest year, and Cue Biopharma's grew 195.8%. Celularity had an operating margin of -230.9%, against -96.7% at Cue Biopharma.

Side by side

CelularityCue Biopharma
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$26M$28M
Revenue growth−51.0%195.8%
Revenue growth a year, last 5 years13.1%53.8%
Gross margin24.4%—
Operating margin−230.9%−96.7%
Net margin−345.4%−96.8%
Free cash flow—−$22M
Free cash flow margin—−79.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count16.9%68.2%
Last close$0.47$4.50
P/E at the last close——
Insider trades, last 12 months—bought $99,719, sold $2.0 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CelularityCue Biopharma
Operating margin
Percent of revenue
CelularityCue Biopharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CelularityCue Biopharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Celularity and Cue Biopharma pages.